PL365024A1 - Inhibitory GLYT-1 - Google Patents
Inhibitory GLYT-1Info
- Publication number
- PL365024A1 PL365024A1 PL02365024A PL36502402A PL365024A1 PL 365024 A1 PL365024 A1 PL 365024A1 PL 02365024 A PL02365024 A PL 02365024A PL 36502402 A PL36502402 A PL 36502402A PL 365024 A1 PL365024 A1 PL 365024A1
- Authority
- PL
- Poland
- Prior art keywords
- glyt
- inhibitors
- substituted amine
- amine derivatives
- thiophene substituted
- Prior art date
Links
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title 2
- 150000001412 amines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229930192474 thiophene Natural products 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26924101P | 2001-02-16 | 2001-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL365024A1 true PL365024A1 (pl) | 2004-12-27 |
Family
ID=23026417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02365024A PL365024A1 (pl) | 2001-02-16 | 2002-02-15 | Inhibitory GLYT-1 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6667336B2 (pl) |
| EP (1) | EP1368336B9 (pl) |
| JP (2) | JP2004523548A (pl) |
| KR (1) | KR100900020B1 (pl) |
| CN (1) | CN1219776C (pl) |
| AT (1) | ATE327986T1 (pl) |
| AU (1) | AU2002235682C1 (pl) |
| BG (1) | BG108164A (pl) |
| BR (1) | BR0207307A (pl) |
| CA (1) | CA2438367A1 (pl) |
| CY (1) | CY1105529T1 (pl) |
| CZ (1) | CZ20032503A3 (pl) |
| DE (1) | DE60211866T2 (pl) |
| DK (1) | DK1368336T3 (pl) |
| EA (1) | EA006636B1 (pl) |
| EE (1) | EE05329B1 (pl) |
| ES (1) | ES2266446T3 (pl) |
| HR (1) | HRP20030696A2 (pl) |
| HU (1) | HUP0303185A3 (pl) |
| IL (1) | IL157194A (pl) |
| MX (1) | MXPA03007309A (pl) |
| NO (1) | NO329038B1 (pl) |
| NZ (1) | NZ527695A (pl) |
| PL (1) | PL365024A1 (pl) |
| PT (1) | PT1368336E (pl) |
| SI (1) | SI1368336T1 (pl) |
| SK (1) | SK287304B6 (pl) |
| UA (1) | UA75114C2 (pl) |
| WO (1) | WO2002066456A2 (pl) |
| ZA (1) | ZA200307201B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6191165B1 (en) * | 1996-05-31 | 2001-02-20 | Allelix Neuroscience Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| EP1830833B1 (en) * | 2004-12-16 | 2010-01-27 | Janssen Pharmaceutica N.V. | Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
| US20090253918A1 (en) * | 2006-10-02 | 2009-10-08 | Janssen Pharmaceuticals, N.V. | Novel intermediate for glyt1 inhibitor |
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| CN103374057B (zh) * | 2012-04-16 | 2015-08-19 | 中国医药集团总公司四川抗菌素工业研究所 | 一种对甘氨酸转运子具有抑制活性的化合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3050800C2 (pl) | 1979-03-22 | 1989-06-22 | Continental Pharma Inc., Bruessel/Bruxelles, Be | |
| BE885303A (fr) | 1980-09-19 | 1981-03-19 | Continental Pharma | Glycinamides |
| AU552050B2 (en) | 1981-05-26 | 1986-05-22 | Smithkline Beckman Corporation | N-substituted azeheterocyclic carboxylic acids and their esters |
| US4383999A (en) | 1981-05-26 | 1983-05-17 | Smithkline Beckman Corporation | Inhibition of GABA uptake by N-substituted azaheterocyclic carboxylic acids and their esters |
| US4514414A (en) | 1982-10-25 | 1985-04-30 | Smithkline Beckman Corporation | N-Substituted pyrrolidineacetic acids and their esters |
| DK288385D0 (da) | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
| US4772615A (en) | 1985-11-08 | 1988-09-20 | Warner-Lambert Company | Various N-substituted 3-piperidine carboxylic acids or N-substituted 3-pyridinecarboxylic acids and derivatives thereof |
| FI864246A7 (fi) | 1985-11-08 | 1987-05-09 | Warner Lambert Co | N-substituerade 3-piperidin- eller 3-pyridinkarboxylsyror samt deras derivat. |
| DK165692C (da) | 1986-01-07 | 1993-11-08 | Novo Nordisk As | Phenylbutenderivater, fremgangsmaade til fremstilling heraf, farmaceutisk praeparat indeholdende disse, samt anvendelse af disse til fremstilling af et medikament nyttigt til inhibering af gaba-optagelse i mennesker |
| JPH02129158A (ja) | 1988-11-07 | 1990-05-17 | Nippon Steel Corp | 光学活性なグリシン誘導体及びその製造方法 |
| IE913279A1 (en) * | 1990-09-26 | 1992-04-08 | Astra Ab | (2-Thienyl)alkylamine Derivatives Having Neuroprotective¹Properties |
| ES2036926B1 (es) | 1991-08-08 | 1994-01-16 | Uriach & Cia Sa J | "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina". |
| IL124536A (en) | 1995-12-07 | 2001-03-19 | Daniel C Javitt | Pharmaceutical compositions containing a glycine uptake antagonist |
| US6191165B1 (en) | 1996-05-31 | 2001-02-20 | Allelix Neuroscience Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| IL127244A (en) * | 1996-05-31 | 2005-11-20 | Allelix Neuroscience Inc | Substituted amines, methods of their preparation and pharmaceutical compositions containing them |
| US5922770A (en) * | 1996-07-22 | 1999-07-13 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| PL342763A1 (en) * | 1998-01-09 | 2001-07-02 | Pfizer | Matrix metaloprotease inhibitor |
| US6103743A (en) * | 1999-08-06 | 2000-08-15 | Allelix Neuroscience, Inc. | Unsaturated amino acid derivatives |
-
2002
- 2002-02-15 PT PT02702186T patent/PT1368336E/pt unknown
- 2002-02-15 CA CA002438367A patent/CA2438367A1/en not_active Abandoned
- 2002-02-15 EA EA200300900A patent/EA006636B1/ru not_active IP Right Cessation
- 2002-02-15 KR KR1020037010609A patent/KR100900020B1/ko not_active Expired - Fee Related
- 2002-02-15 CN CNB028050819A patent/CN1219776C/zh not_active Expired - Fee Related
- 2002-02-15 SK SK1144-2003A patent/SK287304B6/sk not_active IP Right Cessation
- 2002-02-15 EE EEP200300394A patent/EE05329B1/xx not_active IP Right Cessation
- 2002-02-15 HR HR20030696A patent/HRP20030696A2/xx not_active Application Discontinuation
- 2002-02-15 AU AU2002235682A patent/AU2002235682C1/en not_active Ceased
- 2002-02-15 UA UA2003087630A patent/UA75114C2/uk unknown
- 2002-02-15 ES ES02702186T patent/ES2266446T3/es not_active Expired - Lifetime
- 2002-02-15 JP JP2002565971A patent/JP2004523548A/ja active Pending
- 2002-02-15 MX MXPA03007309A patent/MXPA03007309A/es active IP Right Grant
- 2002-02-15 NZ NZ527695A patent/NZ527695A/en unknown
- 2002-02-15 DE DE60211866T patent/DE60211866T2/de not_active Expired - Lifetime
- 2002-02-15 EP EP02702186A patent/EP1368336B9/en not_active Expired - Lifetime
- 2002-02-15 HU HU0303185A patent/HUP0303185A3/hu unknown
- 2002-02-15 CZ CZ20032503A patent/CZ20032503A3/cs unknown
- 2002-02-15 US US10/077,579 patent/US6667336B2/en not_active Expired - Fee Related
- 2002-02-15 AT AT02702186T patent/ATE327986T1/de not_active IP Right Cessation
- 2002-02-15 PL PL02365024A patent/PL365024A1/pl unknown
- 2002-02-15 DK DK02702186T patent/DK1368336T3/da active
- 2002-02-15 SI SI200230381T patent/SI1368336T1/sl unknown
- 2002-02-15 BR BR0207307-2A patent/BR0207307A/pt not_active IP Right Cessation
- 2002-02-15 WO PCT/CA2002/000176 patent/WO2002066456A2/en active IP Right Grant
-
2003
- 2003-07-31 IL IL157194A patent/IL157194A/en not_active IP Right Cessation
- 2003-08-15 NO NO20033634A patent/NO329038B1/no not_active IP Right Cessation
- 2003-09-09 BG BG108164A patent/BG108164A/xx unknown
- 2003-09-15 ZA ZA200307201A patent/ZA200307201B/en unknown
-
2006
- 2006-08-22 CY CY20061101160T patent/CY1105529T1/el unknown
-
2009
- 2009-11-09 JP JP2009255663A patent/JP2010059182A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE440603T1 (de) | 8-hydroxychinolinderivate | |
| IL127244A (en) | Substituted amines, methods of their preparation and pharmaceutical compositions containing them | |
| MXPA03006248A (es) | Derivados de acido fumarico como inhibidores de nf-kappab. | |
| JO2311B1 (en) | Alkyl inhibitors Ariel phosphodiesterase-4 | |
| WO2004022528A3 (en) | Arylglycine derivatives and their use as glycine transport inhibitors | |
| ATE272617T1 (de) | Sulfonamid-derivate | |
| WO2002085853A3 (en) | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| CY1105529T1 (el) | Αντικατεστημενα με θειοφαινιο παραγωγα αμυνης σαν glyt-1 αναστολεις | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| TNSN99158A1 (ar) | طريقة لمنع الاصابة بالربو | |
| SE0100295D0 (sv) | New compounds | |
| ZA200400824B (en) | Pyridin-2-yl-methlyamine derivatives for treating opioid dependence. | |
| WO2004035031A3 (en) | Treatment of uveal melanoma | |
| EP1210948B8 (en) | Therapeutic peptide for nervous diseases | |
| MY139844A (en) | 1,2,4-triaminobenzene derivatives and their uses thereof for the prevention, treatment and/or inhibition of disorders of the central nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |